Ozempic: $14 in India Vs. $349 in the US #shorts
Why It Matters
Affordable semaglutide in India could dramatically improve diabetes outcomes for millions and set a precedent for lower drug prices worldwide, while U.S. patients remain locked into high costs until 2032.
Key Takeaways
- •Semaglutide patent expired in India, sparking generic competition.
- •Indian generics drove price from $100 to $14 per month.
- •Novo Nordisk cut its own Indian price to $16 after generics entered.
- •Low-cost semaglutide could aid 100 million Indian diabetics significantly.
- •US price stays high until 2032 patent expiration, limiting access.
Summary
The video highlights a stark price disparity for semaglutide, the active ingredient in Ozempic, which costs $349 a month in the United States but only about $14 in India. The difference stems from the recent expiration of the drug’s patent in India, allowing multiple local manufacturers to produce generic versions.
Within days of the patent lapse, half a dozen Indian firms launched their own semaglutide products, driving the market price down from over $100 to roughly $14 per month. In response, Novo Nordisk, the original maker of Ozempic, slashed its Indian price to $16, a significant reduction but still above the lowest generic price.
The video underscores the public‑health stakes: India’s 100 million diabetics could now access an affordable, proven therapy that also reduces heart‑attack and stroke risk. Moreover, more than 150 developing nations—home to two‑thirds of the world’s diabetics—have never patented the drug, suggesting a broader global impact.
While the United States will not see comparable pricing until the 2032 patent expiry, the Indian price collapse demonstrates how generic competition can transform treatment accessibility and could pressure other markets to reconsider pricing structures.
Comments
Want to join the conversation?
Loading comments...